Nonpeptide endothelin antagonists I
AssigneeWarner-Lambert Company
InventorsKent Alan Berryman, Annette Marian Doherty, Jeremy John Edmunds, William Chester Patt, Mark Stephen Plummer, Joseph Thomas Repine
Life of this patent
Estimating the term…
Loading patent…
AssigneeWarner-Lambert Company
InventorsKent Alan Berryman, Annette Marian Doherty, Jeremy John Edmunds, William Chester Patt, Mark Stephen Plummer, Joseph Thomas Repine
Estimating the term…
Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.
A compound of formula ##STR461## or a tautomeric open chain keto-acid form thereof or a pharmaceutically acceptable salt thereof wherein
A compound selected from 2-benzo-1,3!dioxol-5-yl-4-(4-methoxyphenyl)-4-oxo-3-(3,4,5-trimethoxybenz yl)-but-2-enoic acid and the pharmacologically acceptable salts thereof.
A compound selected from the group:
A compound named:
Dependencies are inferred from the claim text.